Get the Stockscreener App
15.46
5.42%
0.7887
Erasca Inc stock is traded at $15.46, with a volume of 1.94M.
It is up +5.42% in the last 24 hours and up +14.90% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
See More
Previous Close:
$14.67
Open:
$14.9
24h Volume:
1.94M
Relative Volume:
0.33
Market Cap:
$4.81B
Revenue:
-
Net Income/Loss:
$-124.55M
P/E Ratio:
-35.19
EPS:
-0.4393
Net Cash Flow:
$-95.58M
1W Performance:
+14.56%
1M Performance:
+14.90%
6M Performance:
+754.43%
1Y Performance:
+944.94%
1-Day Range:
$14.90
$15.54
1-Week Range:
$13.36
$15.54
52-Week Range:
$1.01
$16.41
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
15.49 | 4.56B | 0 | -124.55M | -95.58M | -0.4393 |
VRTX
Vertex Pharmaceuticals Inc
|
457.90 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
752.46 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
324.52 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
694.18 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.20 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Resumed | Mizuho | Outperform |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-16-25 | Initiated | Stifel | Buy |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Erasca (ERAS) adds 13%; soars 310% YTD - MSN
Assessing Erasca (ERAS) Valuation After ERAS-0015 Licensing Win And Data Anticipation - Yahoo Finance
Certain Stock Options of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - marketscreener.com
TNGX stock hits record high on inking collaboration deal with ERAS - MSN
How Erasca’s Expanded ERAS-0015 License and Narrower 2025 Loss Will Impact Erasca (ERAS) Investors - simplywall.st
Erasca (ERAS) Adds 13%; Soars 310% YTD - Yahoo Finance
5 Stocks Dominating Today’s Market Action - Insider Monkey
Erasca (NASDAQ:ERAS) Shares Up 10.3% on Better-Than-Expected Earnings - MarketBeat
Guggenheim more than doubles Erasca (ERAS) PT following clinical progress and updated pipeline models - MSN
ERAS Surges as JP Morgan Raises Price Target | ERAS Stock News - GuruFocus
JPMorgan Chase & Co. Increases Erasca (NASDAQ:ERAS) Price Target to $25.00 - MarketBeat
Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC), Argenx Se (ARGX) and Erasca (ERAS) - The Globe and Mail
Erasca Inc stock hits 52-week high at $14.63 - Investing.com Nigeria
Erasca, Inc. (NASDAQ:ERAS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Chipmakers Recap: Should I invest in Erasca Inc before earnings2026 Valuation Update & Weekly Sector Rotation Insights - baoquankhu1.vn
Erasca Form 144: Foundation Lists Proposed Common Sales | ERAS SEC FilingForm 144 - Stock Titan
Erasca (NASDAQ:ERAS) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Erasca’s Stock Faces Pressure as CMO Offloads Shares - StocksToTrade
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts - AOL.com
Erasca’s CMO Stock Sale Raises Eyebrows Amid Market Uncertainty - timothysykes.com
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Sahm
Assessing Tango Therapeutics (TNGX) Valuation After Vopimetostat Progress And New Erasca Collaboration - simplywall.st
Erasca secures worldwide rights to RAS-targeting drug ERAS-0015 By Investing.com - Investing.com Nigeria
Erasca’s Chief Medical Officer Divests Shares Amid Strategic Uncertainties - StocksToTrade
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), MindWalk Holdings (HYFT) and Erasca (ERAS) - The Globe and Mail
Bank of America Securities Sticks to Its Sell Rating for Erasca (ERAS) - The Globe and Mail
Erasca (NASDAQ:ERAS) Price Target Raised to $18.00 at Piper Sandler - MarketBeat
Erasca stock price target raised to $20 by H.C. Wainwright on trial data - Investing.com Nigeria
Erasca (NASDAQ:ERAS) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
Erasca (NASDAQ:ERAS) Given New $20.00 Price Target at HC Wainwright - MarketBeat
Stifel reiterates Buy rating on Erasca stock, $20 target By Investing.com - Investing.com Canada
Stifel reiterates Buy rating on Erasca stock, $20 target - Investing.com
Decoding Erasca Inc (ERAS): A Strategic SWOT Insight - GuruFocus
Erasca, Inc. 2025 Annual Report: Erasing Cancer with Modality-Agnostic RAS/MAPK Pathway Therapeutics and Innovative Precision Oncology Strategies - Minichart
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results - The Manila Times
Erasca 10-K: Net loss $124.55M; cash and securities $341.8M - TradingView
Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Erasca (NASDAQ: ERAS) narrows 2025 loss and funds runway into H2 2028 - Stock Titan
Cancer-drug maker Erasca raises $259M, says cash lasts to 2028 - Stock Titan
A Look At Erasca (ERAS) Valuation After Securing Global Rights To ERAS-0015 - simplywall.st
Erasca (ERAS) to Release Earnings on Thursday - MarketBeat
Stifel raises Erasca stock price target to $20 on China expansion - Investing.com India
Stifel raises Erasca stock price target to $20 on China expansion By Investing.com - Investing.com South Africa
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):